Prasugrel

Antiplatelet Therapy

      -In ACS and PCI: Challenges and Future Directions by Dr. Stephen D. Wiviott (2007)

      -Use After Discharge Among Acute Myocardial Infarction Patients with In-Hospital Bleeding by Dr. Tracy Y. Wang (2008)

ARCTIC: Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation

    -A Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy by Dr. Jean-Philippe Collet (TCT 2010)

    -Trial Overview by Dr. Gilles Montalescot (AHA 2012)

Clopidogrel Non-responsiveness

      -Clinical Implications of Clopidogrel Non-responsiveness by Dr. Dominick Angiolillo (2007)

 

PRO-GR: High-Dose Clopidogrel vs. Prasugrel in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele

      -A Prospective, Randomized, Crossover Study of Maintenance High-Dose Clopidogrel vs. Prasugrel in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele by Dr. Dimitrios Alexopoulos (TCT 2010)

 

RAPID GENE: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in CYP2C19*2 Carriers Identified by Rapid Point-of-Care Genotyping

      -Trial Overview by Dr. Derek So (TCT 2011)

 

RESET GENE: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel.

      -Study Overview by Dr. Gennaro Sardella (ACC 2012)

 

TRIGGER-PCI: Testing Platelet Reactivity in Patients Undergoing Elective Stent Replacement on Clopidogrel to Guide Alternative Therapy with Prasugrel

      -Primary Results by Dr. Dietmar Trenk (TCT 2011)

TRILOGY ACS: Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After Coronary Angiography

      -Prasugrel versus clopidogrel for patients with unstable angina/NSTEMI who are medically managed without revascularization by Dr. Matthew Roe and Dr. Magnus Ohman (ESC 2012)

      -Trial Results by Dr. Stephen D. Wiviott et al. (TCT 2012, AHA 2012)

TRILOGY ACS Platelet Function Sub-study: First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndromes Trial

      -Trial Overview by Dr. Paul Gurbel and Dr. Magnus Ohman (AHA 2012)

TRITON TIMI-38 STEMI: Trial To Assess Improvement In Therapeutic Outcomes By Optimizing Platelet Inhibition With Prasugrel - Thrombolysis In Myocardial Infarction 38

      -Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON TIMI-38 by Dr. Gilles Montalescot, et al.

      -The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial by Dr. Michelle O'Donoghue, et al. (ESC 2009)

      -TRITON-TIMI 38 Economic Substudy: Cost-effectiveness of Prasugrel vs. Clopidogrel for PCI Patients with Acute Coronary Syndromes by Dr. David J. Cohen, et al.

 

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

© 1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster